NCT05327491 A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets Status COMPLETED Phase PHASE1
NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression Status COMPLETED Phase PHASE1/PHASE2
NCT05323617 Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy Status WITHDRAWN Phase PHASE2
NCT05322577 A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT05317078 A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications Status TERMINATED Phase PHASE1
NCT05284747 EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction Status ACTIVE_NOT_RECRUITING Phase PHASE4
NCT05267470 A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) Status TERMINATED Phase PHASE1
NCT05251038 Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer Status WITHDRAWN Phase PHASE1/PHASE2
NCT05209152 AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia Status TERMINATED Phase PHASE1
NCT05198934 Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation Status COMPLETED Phase PHASE3
NCT05180422 A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis Status WITHDRAWN Phase PHASE1/PHASE2
NCT05174065 Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP) Status COMPLETED Phase PHASE3
NCT05162027 Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE) Status TERMINATED Phase PHASE2
NCT05142228 Erenumab-aooe for the Management of Trigeminal Neuropathic Pain. Status TERMINATED Phase PHASE2